Sasha Bakhru
Directeur Général chez Perosphere, Inc.
Profil
Sasha H.
Bakhru is the founder of Perosphere, Inc. In 2011, he became the Chief Scientific Officer, SEVP, CEO & President of the company.
Postes actifs de Sasha Bakhru
| Sociétés | Poste | Début |
|---|---|---|
Perosphere, Inc.
 Perosphere, Inc. Pharmaceuticals: MajorHealth Technology Perosphere, Inc. operates as a pharmaceutical company that focuses on addressing unmet medical needs associated with anticoagulant therapies. Its drug product candidate, ciraparantag, is an intravenously administered small synthetic water soluble new molecular entity rationally designed for use as a broad-spectrum reversal agent for anticoagulants including heparins and the new oral anticoagulants allowing rapid re-establishment of a normal blood coagulation state when clinically indicated. The firm's device product candidate is point-of-care coagulometer, a hand-held device that tests fresh or citrated whole blood. The system is designed for broad-spectrum monitoring of the activity of anticoagulants and their corresponding antidotes, across drug classes, in a hospital setting at a patient's bedside. The company was founded by Sasha H. Bakhru, Edith Mathiowitz, Bryan E. Laulicht and Solomon S. Steiner in 2011 and is headquartered in Danbury, CT. | Directeur Général | 01/01/2011 |
Perosphere Technologies, Inc.
 Perosphere Technologies, Inc. Packaged SoftwareTechnology Services Perosphere Technologies, Inc. is a private medical technologies company that is focused on developing and commercializing the novel POC (point-of-care) coagulometer. The company is based in Danbury, CT. This diagnostic tool informs diagnosis, treatment, and prevention through precision data, made immediately accessible to all. The POC coagulometer is the only point-of-care diagnostic tool that effectively and swiftly tests clotting times across drug classes, including direct oral anticoagulants (DOACs). The fast diagnosis and related appropriate treatment decisions the POC coagulometer enables will help establish a new standard of care in hospital emergency departments for patients at risk for bleeding and has the potential to improve efficiency, provide significant cost savings, and better patient outcomes. The CEO of the company is Sasha H. Bakhru. | Directeur Général | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Perosphere, Inc.
Perosphere, Inc. Pharmaceuticals: MajorHealth Technology Perosphere, Inc. operates as a pharmaceutical company that focuses on addressing unmet medical needs associated with anticoagulant therapies. Its drug product candidate, ciraparantag, is an intravenously administered small synthetic water soluble new molecular entity rationally designed for use as a broad-spectrum reversal agent for anticoagulants including heparins and the new oral anticoagulants allowing rapid re-establishment of a normal blood coagulation state when clinically indicated. The firm's device product candidate is point-of-care coagulometer, a hand-held device that tests fresh or citrated whole blood. The system is designed for broad-spectrum monitoring of the activity of anticoagulants and their corresponding antidotes, across drug classes, in a hospital setting at a patient's bedside. The company was founded by Sasha H. Bakhru, Edith Mathiowitz, Bryan E. Laulicht and Solomon S. Steiner in 2011 and is headquartered in Danbury, CT. | Health Technology |
Perosphere Technologies, Inc.
Perosphere Technologies, Inc. Packaged SoftwareTechnology Services Perosphere Technologies, Inc. is a private medical technologies company that is focused on developing and commercializing the novel POC (point-of-care) coagulometer. The company is based in Danbury, CT. This diagnostic tool informs diagnosis, treatment, and prevention through precision data, made immediately accessible to all. The POC coagulometer is the only point-of-care diagnostic tool that effectively and swiftly tests clotting times across drug classes, including direct oral anticoagulants (DOACs). The fast diagnosis and related appropriate treatment decisions the POC coagulometer enables will help establish a new standard of care in hospital emergency departments for patients at risk for bleeding and has the potential to improve efficiency, provide significant cost savings, and better patient outcomes. The CEO of the company is Sasha H. Bakhru. | Technology Services |
